Newton Charles W.
SEC CIK 1866219 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | Dir | 12.1K | — | $11.2K | 3 | 2026-03-09 | 2026-08-18 |
| CHRS | Coherus Oncology, Inc. | Dir | 30.0K | — | — | 1 | 2026-06-05 | 2026-06-05 |
| NVAX | NOVAVAX INC | Dir | 9,520 | — | — | 1 | 2026-04-25 | 2026-04-25 |
| LYEL | Lyell Immunopharma, Inc. | CFO | 15.3K | $112.0K | $18.1K | 6 | 2024-02-09 | 2025-08-21 |
Most active insiders at KROS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneeberger Daniel | 10% | — | $95.66M |
| 2 | Pontifax (China) IV L.P. | 10% | — | $84.98M |
| 3 | Cho Esther | SVP, GC | — | $123.7K |
| 4 | Seehra Jasbir | CEO, Dir | — | $113.4K |
| 5 | Lerner Lorena Raquel | CSO | — | $100.0K |
| 6 | Regnante Keith | CFO | — | $77.5K |
| 7 | BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| 8 | Knowles Julius | Dir | — | $28.2K |
| 9 | Farzan Nima | Dir | — | $28.2K |
| 10 | Seth Alpna | Dir | — | $28.1K |
| 12 | Newton Charles W. | Dir | — | $11.2K |
Transactions 11
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-20 16:10 | 2026-08-18 | KROS | Keros Therapeutics, Inc. | Newton Charles W. | Dir | S - Sale | $10.30 | -551 | 12.1K | -4% | -$5,675 |
| T | 2026-06-15 16:15 | 2026-06-11 | KROS | Keros Therapeutics, Inc. | Newton Charles W. | Dir | S - Sale | $10.04 | -550 | 12.7K | -4% | -$5,522 |
| D | 2026-06-09 18:39 | 2026-06-05 | CHRS | Coherus Oncology, Inc. | Newton Charles W. | Dir | A - Grant | $0.00 | +30.0K | 30.0K | New | $0 |
| D | 2026-04-28 17:00 | 2026-04-25 | NVAX | NOVAVAX INC | Newton Charles W. | Dir | M - OptEx | $0.00 | +9,520 | 9,520 | New | $0 |
| D | 2026-03-11 | 2026-03-09 | KROS | Keros Therapeutics, Inc. | Newton Charles W. | Dir | A - Grant | $0.00 | +13.2K | 13.2K | New | $0 |
| 2025-08-22 | 2025-08-20 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | A - Grant | $0.00 | +8,000 | 16.8K | +91% | $0 | |
| 2025-08-22 | 2025-08-21 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | S - Sale | $10.54 | -1,453 | 15.3K | -9% | -$15.3K | |
| M | 2025-08-13 | 2025-08-11+ | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | S - Sale | $10.43 | -267 | 8,895 | -3% | -$2,786 |
| I | 2025-03-18 | 2025-03-17 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | P - Purchase | $0.56 | +200.0K | 200.0K | New | +$112.0K |
| D | 2025-02-26 | 2025-02-10 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | A - Grant | $0.00 | +112.5K | 172.7K | +187% | $0 |
| D | 2024-02-13 | 2024-02-09 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | CFO | A - Grant | $0.00 | +40.0K | 48.7K | +458% | $0 |
Purchase Sale Sale after option exercise All abbreviations